Phase I/II90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma

✍ Scribed by Gregory A. Wiseman; Christine A. White; Michael Stabin; William L. Dunn; William Erwin; Magnus Dahlbom; Andrew Raubitschek; Kastytis Karvelis; Timothy Schultheiss; Thomas E. Witzig; Richard Belanger; Stewart Spies; Daniel H. S. Silverman; Judy R. Berlfein; Eric Ding; Antonio J. Grillo-López

• Book ID: 105964620
• Publisher: Springer
• Year: 2000
• Tongue: English
• Weight: 166 KB
• Volume: 27
• Category: Article
• ISSN: 0340-6997
• DOI: 10.1007/s002590000276